Mr. Chris Dallin reports

ASEP MEDICAL HOLDINGS ANNOUNCES UP TO C$1,165,000 LIFE OFFERING

ASEP Medical Holdings Inc. intends to complete an offering consisting of up to 5,547,619 units of the company at a price of 21 cents per unit to raise aggregate gross proceeds up to $1,165,000. Each unit will comprise one common share in the authorized share structure of the company and one share purchase warrant. Each warrant will be subject to a 60-day hold period and will entitle the holder thereof to purchase one share at an exercise price of 28 cents for 36 months following the completion of the offering.

The units to be issued under the offering will be offered to purchasers pursuant to the listed issuer financing exemption (LIFE) under Part 5A.2 of National Instrument 45-106, Prospectus Exemptions, as amended by the Canadian Securities Administrators' Coordinated Blanket Order 45-935, Exemption from Certain Conditions of the Listed Issuer Financing Exemption, in all the provinces of Canada, except Quebec. The units offered under the listed issuer financing exemption will not be subject to resale restrictions pursuant to applicable Canadian securities laws.

There is an offering document related to the offering that can be accessed under the company's profile on SEDAR+ and on the company's website. Prospective investors should read the offering document before making an investment decision.

The company plans to use the net proceeds from the offering for research and development, repayment of existing debts, and general working capital purposes and as otherwise described in the offering document. The offering is scheduled to close on or about March 31, 2026, and is subject to certain conditions customary for transactions of this nature, including, but not limited to, the receipt of all necessary approvals, including the approval of the Canadian Securities Exchange.

About ASEP Medical Holdings Inc.

ASEP is a standout biotechnology research and development company based in Victoria, B.C., Canada. The company possesses a valuable portfolio of global patents for innovative diagnostic and therapeutic medical technologies. These technologies were developed over the past decade at the University of British Columbia under the guidance of Dr. Robert E.W. Hancock, one of the world's foremost microbiologists and the chief executive officer of ASEP. ASEP holds a controlling interest in two private subsidiary companies -- Sepset Biosciences (ASEP's leading product, a sepsis diagnostic technology) and ABT Innovations (specializing in anti-biofilm technology). As the company's patented innovations address unmet medical needs, it presents a unique investment opportunity for both retail and institutional investors. It is also an attractive buyout target for a major global pharmaceutical operator.

We seek Safe Harbor.